Newly diagnosed metastatic hormone sensitive prostate cancer
Conditions
Interventions
None listed
Sponsors
Janssen-Cilag B.V.
Eligibility
Inclusion criteria
Inclusion criteria: Male, 18 years or older aged Must have a confirmed newly diagnosis of metastatic hormone sensitive prostate cancer. Must sign a participation agreement/ICF allowing data collection and source data verification in accordance with local requirements
Exclusion criteria
Exclusion criteria: Currently enrolled in an investigational interventional study Currently enrolled in an observational study sponsored or managed by a Janssen company Patients with insufficient understanding of the Dutch language or cognitive impairment that impede proper answering of the questionnaires
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) A comprehensive selection of PROM questionnaires are collected at pre-defined time points, enables comparison of health-related Quality-of-Life. 2) Comparison of clinical effectiveness between treatments. 3) Description of medical resource utilization and health economics. 4) Description of trends and variations in outcomes, diagnostic methods and treatment patterns for newly diagnosed mHSPC over time | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, progression-free survival, duration of treatments, changes to treatment, reasons for initiation/alteration/termination of anti-cancer treatment | — |
Contacts
Public ContactKarien Lieverse
Janssen-Cilag B.V.
Outcome results
None listed